# Certara Reports First Quarter 2026 Financial Results
Canonical URL: https://biopharmsignal.com/news/CERT/certara-reports-first-quarter-2026-financial-results
Ticker: CERT
Company: Certara
Source: Certara
Published: 2026-05-11 10:25 EST
Original Source URL: https://ir.certara.com
## Summary

Updates 2026 Guidance to reflect completed divestiture of Regulatory Writing and Medical Writing Business RADNOR, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its first quarter 2026 financial results.

## Article Body
Updates 2026 Guidance to reflect completed divestiture of Regulatory Writing and Medical Writing Business RADNOR, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its first quarter 2026 financial results.
## Recent Company News
- 2026-05-11 10:25 EST — [Certara Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/CERT/certara-reports-first-quarter-2026-financial-results) — Source: Certara
- 2026-04-22 11:00 EST — [Certara Enters Definitive Agreement for the Sale of its Regulatory and Medical Writing Business to Veristat](https://biopharmsignal.com/news/CERT/certara-enters-definitive-agreement-for-the-sale-of-its-regulatory-and-medical-writing-business-to-veristat) — Source: Certara
- 2026-04-09 20:15 EST — [Certara to Report First Quarter 2026 Financial Results on May 11th, 2026](https://biopharmsignal.com/news/CERT/certara-to-report-first-quarter-2026-financial-results-on-may-11th-2026) — Source: Certara
- 2026-03-03 13:00 EST — [Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib](https://biopharmsignal.com/news/CERT/certara-simcypr-simulator-results-replace-ten-human-trials-for-chronic-myeloid-leukemia-cml-therapy-asciminib) — Source: Certara
- 2026-02-27 13:30 EST — [Certara to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/CERT/certara-to-participate-in-upcoming-investor-conferences) — Source: Certara
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)